Advicenne S.A. (ALDVI.PA)
EUR 1.67
(0.12%)
EUR 1.67
(0.12%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 12.4 Million EUR | -12.99% |
| 2022 | 14.25 Million EUR | -24.48% |
| 2021 | 18.88 Million EUR | -21.34% |
| 2020 | 24 Million EUR | 4.73% |
| 2019 | 22.91 Million EUR | -30.91% |
| 2018 | 33.17 Million EUR | -14.09% |
| 2017 | 38.61 Million EUR | 1086.02% |
| 2016 | 3.25 Million EUR | 9.26% |
| 2015 | 2.98 Million EUR | -7.51% |
| 2014 | 3.22 Million EUR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 7.96 Million EUR | -35.77% |
| 2024 Q2 | 7.96 Million EUR | 0.0% |
| 2023 Q1 | 10.7 Million EUR | -24.94% |
| 2023 FY | 12.4 Million EUR | -12.99% |
| 2023 Q4 | 12.4 Million EUR | 0.0% |
| 2023 Q3 | 12.4 Million EUR | 15.92% |
| 2023 Q2 | 10.7 Million EUR | 0.0% |
| 2022 FY | 14.25 Million EUR | -24.48% |
| 2022 Q4 | 14.25 Million EUR | 0.0% |
| 2022 Q3 | 14.25 Million EUR | 3.93% |
| 2022 Q2 | 13.72 Million EUR | 0.0% |
| 2022 Q1 | 13.72 Million EUR | -27.33% |
| 2021 Q3 | 18.88 Million EUR | -21.74% |
| 2021 Q1 | 24.12 Million EUR | 0.5% |
| 2021 FY | 18.88 Million EUR | -21.34% |
| 2021 Q4 | 18.88 Million EUR | 0.0% |
| 2021 Q2 | 24.12 Million EUR | 0.0% |
| 2020 FY | 24 Million EUR | 4.73% |
| 2020 Q4 | 24 Million EUR | 0.0% |
| 2020 Q1 | 24.89 Million EUR | 8.61% |
| 2020 Q2 | 24.89 Million EUR | 0.0% |
| 2020 Q3 | 24 Million EUR | -3.57% |
| 2019 FY | 22.91 Million EUR | -30.91% |
| 2019 Q2 | 28.33 Million EUR | 0.0% |
| 2019 Q1 | 28.33 Million EUR | -14.6% |
| 2019 Q4 | 22.91 Million EUR | -4.02% |
| 2019 Q3 | 23.87 Million EUR | -15.71% |
| 2018 Q4 | 33.17 Million EUR | 0.0% |
| 2018 FY | 33.17 Million EUR | -14.09% |
| 2018 Q3 | 33.17 Million EUR | -5.22% |
| 2018 Q2 | 35 Million EUR | 0.0% |
| 2018 Q1 | 35 Million EUR | -9.37% |
| 2017 Q2 | 16.56 Million EUR | 0.0% |
| 2017 Q3 | 38.53 Million EUR | 132.67% |
| 2017 Q4 | 38.61 Million EUR | 0.22% |
| 2017 FY | 38.61 Million EUR | 1086.02% |
| 2017 Q1 | 16.56 Million EUR | 408.63% |
| 2016 Q3 | 3.25 Million EUR | 0.0% |
| 2016 Q1 | - EUR | 0.0% |
| 2016 Q4 | 3.25 Million EUR | 0.0% |
| 2016 FY | 3.25 Million EUR | 9.26% |
| 2015 FY | 2.98 Million EUR | -7.51% |
| 2014 FY | 3.22 Million EUR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| ABIONYX Pharma SA | 14.71 Million EUR | 15.656% |
| ABIVAX Société Anonyme | 327.06 Million EUR | 96.207% |
| Adocia SA | 24.95 Million EUR | 50.285% |
| Aelis Farma SA | 26.28 Million EUR | 52.791% |
| Biophytis S.A. | 11.93 Million EUR | -3.946% |
| genOway Société anonyme | 31.84 Million EUR | 61.036% |
| IntegraGen SA | 8 Million EUR | -55.081% |
| Medesis Pharma S.A. | 1.92 Million EUR | -544.073% |
| Neovacs S.A. | 47.53 Million EUR | 73.898% |
| NFL Biosciences SA | 3.97 Million EUR | -212.469% |
| Plant Advanced Technologies SA | 14.91 Million EUR | 16.804% |
| Quantum Genomics Société Anonyme | 3.74 Million EUR | -231.138% |
| Sensorion SA | 46.49 Million EUR | 73.315% |
| Theranexus Société Anonyme | 7.23 Million EUR | -71.421% |
| TME Pharma N.V. | 2.49 Million EUR | -398.073% |
| Valbiotis SA | 33.24 Million EUR | 62.683% |
| TheraVet SA | 7.53 Million EUR | -64.676% |
| Valerio Therapeutics Société anonyme | 35.27 Million EUR | 64.827% |
| argenx SE | 4.11 Billion EUR | 99.698% |
| BioSenic S.A. | 9.55 Million EUR | -29.794% |
| Celyad Oncology SA | 16.28 Million EUR | 23.799% |
| DBV Technologies S.A. | 165.65 Million USD | 92.51% |
| Galapagos NV | 4.35 Billion EUR | 99.715% |
| Genfit S.A. | 173.87 Million EUR | 92.864% |
| GeNeuro SA | 6.31 Million EUR | -96.534% |
| Hyloris Pharmaceuticals SA | 47.68 Million EUR | 73.979% |
| Innate Pharma S.A. | 184.19 Million EUR | 93.264% |
| Inventiva S.A. | 69.13 Million EUR | 82.055% |
| MaaT Pharma SA | 42.93 Million EUR | 71.1% |
| MedinCell S.A. | 36.94 Million EUR | 66.42% |
| Nanobiotix S.A. | 93.89 Million EUR | 86.787% |
| Onward Medical N.V. | 43.62 Million EUR | 71.562% |
| Oryzon Genomics S.A. | 106.9 Million EUR | 88.394% |
| OSE Immunotherapeutics SA | 81.9 Million EUR | 84.851% |
| Oxurion NV | 6.55 Million EUR | -89.42% |
| Pharming Group N.V. | 426.33 Million EUR | 97.09% |
| Poxel S.A. | 4.82 Million EUR | -157.247% |
| GenSight Biologics S.A. | 9.08 Million EUR | -36.536% |
| Transgene SA | 45.21 Million EUR | 72.561% |
| Financière de Tubize SA | 1.92 Billion EUR | 99.354% |
| UCB SA | 15.53 Billion EUR | 99.92% |
| Valneva SE | 469.39 Million EUR | 97.357% |
| Vivoryon Therapeutics N.V. | 30.82 Million EUR | 59.755% |